O	0	7	Helping
O	8	16	patients
O	17	21	make
O	22	30	informed
O	31	38	choices
O	38	39	:
O	40	41	a
O	42	52	randomized
O	53	58	trial
O	59	61	of
O	62	63	a
O	64	72	decision
O	73	76	aid
O	77	80	for
O	81	89	adjuvant
O	90	102	chemotherapy
O	103	105	in
O	106	111	lymph
O	112	116	node
O	116	117	-
O	117	125	negative
O	126	132	breast
O	133	139	cancer
O	139	140	.

O	141	143	In
O	144	150	recent
O	151	156	years
O	156	157	,
O	158	166	patients
O	167	171	have
O	172	181	indicated
O	182	183	a
O	184	190	desire
O	191	194	for
O	195	199	more
O	200	211	information
O	212	217	about
O	218	223	their
O	224	231	disease
O	232	235	and
O	236	238	to
O	239	241	be
O	242	250	involved
O	251	253	in
O	254	260	making
O	261	270	decisions
O	271	276	about
O	277	282	their
O	283	287	care
O	287	288	.

O	289	291	We
O	292	301	developed
O	302	304	an
O	305	308	aid
O	309	315	called
O	316	319	the
O	320	321	"
O	321	329	Decision
O	330	335	Board
O	335	336	"
O	337	339	to
O	340	344	help
O	345	355	clinicians
O	356	362	inform
O	363	371	patients
O	372	376	with
O	377	382	lymph
O	383	387	node
O	387	388	-
O	388	396	negative
O	397	403	breast
O	404	410	cancer
O	411	413	of
O	414	417	the
O	418	423	risks
O	424	427	and
O	428	436	benefits
O	437	439	of
O	440	448	adjuvant
O	449	461	chemotherapy
O	461	462	.

O	463	465	We
O	466	476	determined
O	477	484	whether
O	485	491	adding
O	492	495	the
O	496	504	Decision
O	505	510	Board
O	511	513	to
O	514	517	the
O	518	525	medical
O	526	538	consultation
O	539	547	improved
O	548	555	patient
O	556	565	knowledge
O	566	569	and
O	570	582	satisfaction
O	583	591	compared
O	592	596	with
O	597	600	the
O	601	608	medical
O	609	621	consultation
O	622	627	alone
O	627	628	.

O	629	636	Between
O	637	644	October
O	645	649	1995
O	650	653	and
O	654	659	March
O	660	664	2000
O	664	665	,
B-total-participants	666	669	176
B-eligibility	670	675	women
I-eligibility	676	680	with
I-eligibility	681	686	lymph
I-eligibility	687	691	node
I-eligibility	691	692	-
I-eligibility	692	700	negative
I-eligibility	701	707	breast
I-eligibility	708	714	cancer
I-eligibility	715	718	who
I-eligibility	719	723	were
I-eligibility	724	734	candidates
I-eligibility	735	738	for
I-eligibility	739	747	adjuvant
I-eligibility	748	760	chemotherapy
O	761	765	were
O	766	774	randomly
O	775	783	assigned
O	784	786	to
O	787	794	receive
O	795	798	the
B-intervention	799	807	Decision
I-intervention	808	813	Board
I-intervention	814	818	plus
I-intervention	819	822	the
I-intervention	823	830	medical
I-intervention	831	843	consultation
O	844	845	(
B-intervention-participants	845	847	83
O	848	856	patients
O	856	857	)
O	858	860	or
O	861	864	the
B-control	865	872	medical
I-control	873	885	consultation
I-control	886	891	alone
O	892	893	(
B-control-participants	893	895	93
O	896	904	patients
O	904	905	)
O	905	906	.

O	907	910	One
O	911	915	week
O	916	921	after
O	922	925	the
O	926	938	consultation
O	938	939	,
O	940	948	patients
O	949	958	completed
O	959	960	a
O	961	974	questionnaire
O	975	984	assessing
O	985	990	their
O	991	1000	knowledge
O	1001	1006	about
O	1007	1013	breast
O	1014	1020	cancer
O	1021	1024	and
O	1025	1037	chemotherapy
O	1037	1038	.

O	1039	1051	Satisfaction
O	1052	1056	with
O	1057	1065	decision
O	1066	1072	making
O	1073	1076	was
O	1077	1085	assessed
O	1086	1087	1
O	1088	1092	week
O	1093	1096	and
O	1097	1098	3
O	1098	1099	,
O	1100	1101	6
O	1101	1102	,
O	1103	1106	and
O	1107	1109	12
O	1110	1116	months
O	1117	1122	after
O	1123	1136	randomization
O	1136	1137	,
O	1138	1141	and
O	1142	1153	differences
O	1154	1161	between
O	1162	1168	groups
O	1169	1173	were
O	1174	1182	analyzed
O	1183	1185	by
O	1186	1187	a
O	1188	1196	repeated
O	1197	1205	measures
O	1206	1214	analysis
O	1215	1217	of
O	1218	1226	variance
O	1226	1227	.

O	1228	1231	All
O	1232	1243	statistical
O	1244	1249	tests
O	1250	1254	were
O	1255	1258	two
O	1258	1259	-
O	1259	1264	sided
O	1264	1265	.

O	1266	1274	Patients
O	1275	1277	in
O	1278	1281	the
O	1282	1290	Decision
O	1291	1296	Board
O	1297	1300	arm
O	1301	1305	were
B-outcome	1306	1312	better
I-outcome	1313	1321	informed
O	1322	1327	about
O	1328	1334	breast
O	1335	1341	cancer
O	1342	1345	and
O	1346	1354	adjuvant
O	1355	1367	chemotherapy
O	1368	1372	than
O	1373	1381	patients
O	1382	1384	in
O	1385	1388	the
O	1389	1396	control
O	1397	1400	arm
O	1401	1402	(
O	1402	1406	mean
O	1407	1416	knowledge
O	1417	1422	score
O	1423	1424	=
B-iv-cont-mean	1425	1427	80
I-iv-cont-mean	1427	1428	.
I-iv-cont-mean	1428	1429	2
O	1430	1431	[
O	1431	1433	on
O	1434	1435	a
O	1436	1441	scale
O	1442	1444	of
O	1445	1446	0
O	1446	1447	-
O	1447	1450	100
O	1450	1451	]
O	1451	1452	,
O	1453	1455	95
O	1455	1456	%
O	1457	1467	confidence
O	1468	1476	interval
O	1477	1478	[
O	1478	1480	CI
O	1480	1481	]
O	1482	1483	=
O	1484	1486	77
O	1486	1487	.
O	1487	1488	1
O	1489	1491	to
O	1492	1494	83
O	1494	1495	.
O	1495	1496	3
O	1496	1497	,
O	1498	1501	and
B-cv-cont-mean	1502	1504	71
I-cv-cont-mean	1504	1505	.
I-cv-cont-mean	1505	1506	7
O	1506	1507	,
O	1508	1510	95
O	1510	1511	%
O	1512	1514	CI
O	1515	1516	=
O	1517	1519	69
O	1519	1520	.
O	1520	1521	0
O	1522	1524	to
O	1525	1527	74
O	1527	1528	.
O	1528	1529	4
O	1529	1530	,
O	1531	1543	respectively
O	1543	1544	;
O	1545	1546	P
O	1546	1547	<
O	1547	1548	.
O	1548	1551	001
O	1551	1552	)
O	1552	1553	.

O	1554	1558	Over
O	1559	1562	the
O	1563	1569	entire
O	1570	1575	study
O	1576	1582	period
O	1582	1583	,
B-outcome	1584	1596	satisfaction
O	1597	1601	with
O	1602	1610	decision
O	1611	1617	making
O	1618	1621	was
O	1622	1628	higher
O	1629	1632	for
O	1633	1641	patients
O	1642	1644	in
O	1645	1648	the
O	1649	1657	Decision
O	1658	1663	Board
O	1664	1667	arm
O	1668	1672	than
O	1673	1676	for
O	1677	1685	patients
O	1686	1688	in
O	1689	1692	the
O	1693	1700	control
O	1701	1704	arm
O	1705	1706	(
O	1706	1707	P
O	1708	1709	=
O	1709	1710	.
O	1710	1713	032
O	1713	1714	)
O	1714	1715	.

O	1716	1721	There
O	1722	1725	was
O	1726	1728	no
O	1729	1742	statistically
O	1743	1754	significant
O	1755	1765	difference
O	1766	1773	between
O	1774	1777	the
O	1778	1781	two
O	1782	1788	groups
O	1789	1791	in
O	1792	1795	the
B-outcome	1796	1802	number
I-outcome	1803	1805	of
I-outcome	1806	1814	patients
I-outcome	1815	1818	who
I-outcome	1819	1824	chose
I-outcome	1825	1833	adjuvant
I-outcome	1834	1846	chemotherapy
O	1847	1848	(
B-iv-bin-percent	1848	1850	77
I-iv-bin-percent	1850	1851	%
O	1852	1855	and
B-cv-bin-percent	1856	1858	70
I-cv-bin-percent	1858	1859	%
O	1860	1863	for
O	1864	1872	patients
O	1873	1875	in
O	1876	1879	the
O	1880	1888	Decision
O	1889	1894	Board
O	1895	1898	arm
O	1899	1902	and
O	1903	1908	those
O	1909	1911	in
O	1912	1915	the
O	1916	1923	control
O	1924	1927	arm
O	1927	1928	,
O	1929	1941	respectively
O	1941	1942	;
O	1943	1944	P
O	1945	1946	=
O	1946	1947	.
O	1947	1950	303
O	1950	1951	)
O	1951	1952	.

O	1953	1957	When
O	1958	1964	making
O	1965	1974	decisions
O	1975	1984	regarding
O	1985	1993	adjuvant
O	1994	2006	chemotherapy
O	2006	2007	,
O	2008	2016	patients
O	2017	2021	with
O	2022	2027	early
O	2028	2034	breast
O	2035	2041	cancer
O	2042	2045	who
O	2046	2049	had
O	2050	2054	been
O	2055	2062	exposed
O	2063	2065	to
O	2066	2069	the
O	2070	2078	Decision
O	2079	2084	Board
O	2085	2088	had
O	2089	2095	better
O	2096	2105	knowledge
O	2106	2108	of
O	2109	2112	the
O	2113	2120	disease
O	2121	2124	and
O	2125	2134	treatment
O	2135	2142	options
O	2143	2146	and
O	2147	2154	greater
O	2155	2167	satisfaction
O	2168	2172	with
O	2173	2178	their
O	2179	2187	decision
O	2188	2194	making
O	2195	2199	than
O	2200	2205	those
O	2206	2209	who
O	2210	2218	received
O	2219	2222	the
O	2223	2231	standard
O	2232	2244	consultation
O	2244	2245	.
